Litigation Details for Horizon Medicines LLC v. Alkem Laboratories Ltd. (D. Del. 2018)
✉ Email this page to a colleague
Horizon Medicines LLC v. Alkem Laboratories Ltd. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-07-09 |
| Court | District Court, D. Delaware | Date Terminated | 2020-11-29 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Defendant | Referred To | |
| Parties | ALKEM LABORATORIES LTD. | ||
| Patents | 8,067,033; 8,067,451; 8,309,127; 8,318,202; 8,449,910; 8,501,228 | ||
| Attorneys | Aaron M. Nelson | ||
| Firms | Heyman Enerio Gattuso & Hirzel LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Horizon Medicines LLC v. Alkem Laboratories Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Horizon Medicines LLC v. Alkem Laboratories Ltd. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-07-09 | 1 | Complaint | United States Patent Nos. 8,067,033 (“the ’033 patent”), 8,067,451 (“the ’451 patent”), 8,309,127 (“…910 and ’228 patents. COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,067,033 33…one or more claims of U.S. Patent No. 8,067,033; B. A judgment declaring the…(“the ’127 patent”), 8,318,202 (“the ’202 patent”), 8,449,910 (“the ’910 patent”), and 8,501,228 (“the…. This is an action for patent infringement arising under the patent laws of the United States, | External link to document |
| 2020-07-17 | 168 | Redacted Document | to the asserted claims of U.S. Patent No. 8,067,451 (“the ‘451 patent”) under the doctrine of equivalents… The Asserted Claims of the ‘451 Patent. The ‘451 patent asserted claims (1-3, 8-10) require…layer limitation”) (Ex. 1, the ‘451 patent at 49:54-60). The ‘451 patent specification broadly describes …Limitation of the ‘451 Patent Claims. The asserted claims of the ‘451 patent require that the claimed… A. The Asserted Claims of the ‘451 Patent. .............................................. | External link to document |
| 2020-08-07 | 187 | Memorandum Opinion | infringement of U.S. Patent No. 8,067,033 (“the ’033 patent”) and the ’451 patent. (D.I. 1). Following…construction of one term in U.S. Patent No. 8,067,451 (“the ’451 patent”). The Court has considered the…construction issues concerning the ’033 patent. (D.I. 89.) The ’451 patent is addressed to methods and oral… “It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification | External link to document |
| 2020-08-28 | 200 | Letter | streamlining issues at trial re: infringement of U.S. Patent 8,067,451. (Stover, Chad) (Entered: 08/28/2020) … 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2020-08-31 | 201 | Redacted Document | to inventorship of United States Patent No. 8,067,033 (the “’033 patent”) addressed in connection with … 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2020-09-26 | 218 | POST Trial Brief | Post-Trial Brief Regarding Invalidity of U.S. Patent No. 8,067,033, by Alkem Laboratories Ltd.. (Attachments… 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2020-09-30 | 221 | Redacted Document | Post-Trial Brief Regarding Invalidity of Patent No. 8,067,033, by Alkem Laboratories Ltd.. (Gattuso, Dominick… 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
